Pfizer Inc and GlaxoSmithKline plc today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business. The 2017 global sales for the combined business were approximately $12.7 billion.
L&L Partners advised
Update 12 June 2019: Khaitan & Co acted for
AZB & Partners advised
Primary jurisdiction of deal:
2018-12-19
Deal value: USD 650 million
This deal report is based on a firm's press release and may be only partially complete. Some firms or names of advisers may be therefore be missing.